Cargando…
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
PURPOSE: Circulating tumor cells (CTCs) are prognostic in patients with breast cancer. Several technical platforms exist for their enumeration and characterization. Comparative studies between these platforms are scarce. The RareCyte CTC detection is theoretically more sensitive than the established...
Autores principales: | Dirix, Luc, Buys, Andy, Oeyen, Steffy, Peeters, Dieter, Liègeois, Vincent, Prové, Annemie, Rondas, Dieter, Vervoort, Liesbet, Mariën, Véronique, Laere, Steven Van, Vermeulen, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090706/ https://www.ncbi.nlm.nih.gov/pubmed/35397078 http://dx.doi.org/10.1007/s10549-022-06585-5 |
Ejemplares similares
-
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
por: Dirix, Luc Y., et al.
Publicado: (2022) -
The RareCyte® platform for next‐generation analysis of circulating tumor cells
por: Kaldjian, Eric P., et al.
Publicado: (2018) -
Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte(®) Platform
por: Kaldjian, Eric P., et al.
Publicado: (2022) -
Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer
por: Van der Auwera, I, et al.
Publicado: (2010) -
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
por: Oeyen, Steffi, et al.
Publicado: (2020)